Please use this identifier to cite or link to this item:
Title: Circulating amino acid levels and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition and UK Biobank cohorts
Author: Rothwell, Joseph A.
Bešević, Jelena
Dimou, Niki
Breeur, Marie
Murphy, Neil
Jenab, Mazda
Wedekind, Roland
Viallon, Vivian
Ferrari, Pietro
Achaintre, David
Gicquiau, Audrey
Rinaldi, Sabina
Scalbert, Augustin
Huybrechts, Inge
Prehn, Cornelia
Adamski, Jerzy
Cross, Amanda J.
Keun, Hector
Chadeau-Hyam, Marc
Boutron-Ruault, Marie Christine
Overvad, Kim
Dahm, Christina C.
Nøst, Therese Haugdahl
Sandanger, Torkjel M.
Skeie, Guri
Zamora-Ros, Raul
Tsilidis, Kostas K.
Eichelmann, Fabian
Schulze, Matthias B.
Guelpen, Bethany van
Vidman, Linda
Sánchez, Maria José
Amiano, Pilar
Ardanaz, Eva
Smith-Byrne, Karl
Travis, Ruth
Katzke, Verena
Kaaks, Rudolf
Derksen, Jeroen W. G.
Colorado Yohar, Sandra
Tumino, Rosario
Bueno de Mesquita, Bas
Vineis, Paolo
Palli, Domenico
Pasanisi, Fabrizio
Eriksen, Anne Kirstine
Tjønneland, Anne
Severi, Gianluca
Gunter, Marc J.
Keywords: Càncer colorectal
Colorectal cancer
Amino acids
Issue Date: 28-Feb-2023
Publisher: Springer Science and Business Media LLC
Abstract: BackgroundAmino acid metabolism is dysregulated in colorectal cancer patients; however, it is not clear whether pre-diagnostic levels of amino acids are associated with subsequent risk of colorectal cancer. We investigated circulating levels of amino acids in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) and UK Biobank cohorts.MethodsConcentrations of 13-21 amino acids were determined in baseline fasting plasma or serum samples in 654 incident colorectal cancer cases and 654 matched controls in EPIC. Amino acids associated with colorectal cancer risk following adjustment for the false discovery rate (FDR) were then tested for associations in the UK Biobank, for which measurements of 9 amino acids were available in 111,323 participants, of which 1221 were incident colorectal cancer cases.ResultsHistidine levels were inversely associated with colorectal cancer risk in EPIC (odds ratio [OR] 0.80 per standard deviation [SD], 95% confidence interval [CI] 0.69-0.92, FDR P-value=0.03) and in UK Biobank (HR 0.93 per SD, 95% CI 0.87-0.99, P-value=0.03). Glutamine levels were borderline inversely associated with colorectal cancer risk in EPIC (OR 0.85 per SD, 95% CI 0.75-0.97, FDR P-value=0.08) and similarly in UK Biobank (HR 0.95, 95% CI 0.89-1.01, P=0.09) In both cohorts, associations changed only minimally when cases diagnosed within 2 or 5 years of follow-up were excluded.ConclusionsHigher circulating levels of histidine were associated with a lower risk of colorectal cancer in two large prospective cohorts. Further research to ascertain the role of histidine metabolism and potentially that of glutamine in colorectal cancer development is warranted.
Note: Reproducció del document publicat a:
It is part of: BMC Medicine, 2023, vol. 21, num. 1
Related resource:
ISSN: 1741-7015
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s12916-023-02739-4.pdf1.35 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons